Background & Aims: CCL25 mediates the homeostatic recruitment of CCR9-expressing lymphocytes to the small intestine, but the function of this chemokine/receptor pair during chronic small intestinal inflammation has yet to be determined. Furthermore, although clinical trials to evaluate the efficacy of targeting the CCL25/CCR9 axis for the treatment of Crohn's disease are being conducted, preclinical data in animal models of IBD are lacking. Methods: In the current studies, we investigated the expression of CCL25 and CCR9 as a function of disease progression in a spontaneous murine model of chronic ileitis (SAMP1/YitFc) using flow cytometry, real-time reverse-transcription polymerase chain reaction, enzyme-linked immunosorbent assay, and immunohistochemistry. In addition, we assessed the functional role of the axis in the overall disease process through therapeutic studies that target the chemokine or the receptor during early and late disease.
Results:
The percentage of CCR9-expressing lymphocytes increased during early disease, accompanied by the appearance of a population of CCR9 high lymphocytes, predominantly within CD8 ϩ T cells. Yet different from patients with primary sclerosing cholangitis, the expression of CCL25 remained restricted to the small intestine, even in mice with inflammation of the biliary tree. Neutralization of the receptor or the chemokine attenuated early disease but showed no therapeutic efficacy during the later stages, when overall CCR9 expression decreased and the CCR9 high population was absent. Conclusions: Our studies show that the role of this chemokine axis is not limited to homeostatic recruitment, as previously believed. However, these molecules appear to play their most crucial role during the early stages of chronic murine ileitis.
T he inflammatory bowel diseases (ie, Crohn's disease [CD] and ulcerative colitis) affect distinct intestinal segments. Ulcerative colitis is strictly a colonic disease, whereas CD involves predominantly the small intestine. 1, 2 Therefore, the recirculating effector/memory cell pool, which is responsible for perpetuating the chronic inflammatory process, must express a particular repertoire of adhesion molecules and chemokine receptors ("address code") that allows distinction between the small and large bowels. 3 Recirculation to the intestine in general is mediated by the gut-homing integrin ␣ 4 ␤ 7 , which interacts with its ligand MAdCAM-1, expressed on the intestinal microvascular endothelium and associated lymphoid tissues. 4 However, the molecules that enable recirculation specifically to the small intestine and may explain the preferential small intestinal localization of CD have just begun to be identified.
The expression of the chemokine CCL25/TECK is restricted to the thymus and small intestine. 5 This expression pattern provides molecular evidence for the potential dichotomization of intestinal trafficking into distinct small and large intestinal compartments. 3, 6 CCL25 is produced by small intestinal epithelial cells and serves as a homing beacon for the homeostatic recruitment of lymphocyte subpopulations (eg, immunoglobulin [Ig] A antibody-secreting cells, CD8␣␣ and T cells) to the small intestine. [7] [8] [9] [10] [11] [12] However, it is not known whether CCL25 or its receptor CCR9 participate in effector T-cell recruitment to the chronically inflamed small intestine. To that effect, recent reports have shown that patients with small intestinal CD have an increased number of CCR9 ϩ T cells in the peripheral blood. 13 It has also been shown that CCL25 is induced aberrantly in the chronically inflamed hepatic microvasculature of patients with primary sclerosing cholangitis, a chronic immune-mediated disease of the biliary tree frequently associated with inflammatory bowel disease. 14 These findings imply that the role of CCL25/CCR9 may not be limited to homeostatic recruitment, but rather that this chemokine/receptor pair also participates in chronic inflammatory trafficking.
In the current studies, we used the SAMP1/YitFc mouse model, which develops spontaneous chronic inflammation in the terminal ileum (ie, chronic murine ileitis), to investigate the roles of CCL25/CCR9 during lymphocyte trafficking to the chronically inflamed small intestine. First, we determined whether the expression of CCR9 or of its ligand CCL25 is influenced by the development of chronic inflammation. We found that the number of CCR9-expressing cells increased with disease progression, and a CCR9 high population was present only in inflamed mice at the peak of the disease (8 -10 weeks). Total tissue expression of CCL25 was similarly increased compared with control mice and also as the disease progressed. However, the specific localization of CCL25 to the small intestine was preserved even in mice with inflammatory involvement of the biliary tree. Therapeutic studies probed the functional role of the chemokine/receptor pair in ileitis by targeting the chemokine or its receptor. These studies demonstrate therapeutic efficacy during early but not late disease, suggesting that in the late stages the recruitment process becomes less dependent on this predominantly homeostatic chemokine axis.
Materials and Methods Mice
The SAMP1/YitFc substrain was generated after more than 30 generations of continuous inbreeding from 2 breeding pairs of SAMP1/Yit mice provided by Dr S. Matsumoto (Yakult Institute for Microbiological Research, Tokyo, Japan). Mice were kept under specific pathogen-free conditions at the University of Virginia. 15 Because most identifiable genes were AKR derived, age-matched AKR/J mice were used as controls. 16 Fecal samples from SAMP1/YitFc mice were consistently negative for Helicobacter hepaticus, Helicobacter bilis, and other murine Helicobacter species, as well as for protozoa and helminthes. All animals were handled according to procedures approved by the institutional committee for animal use. CCR9 Ϫ/Ϫ mice were obtained from Dr Paul Love (National Institute of Child Health and Human Development, National Institutes of Health), integrin ␣ E Ϫ/Ϫ mice from Dr Lynn Bry (Brigham & Women's Hospital), and integrin ␤ 7 Ϫ/Ϫ mice from Jackson Laboratories (Bar Harbor, ME). [17] [18] [19] [20] 
Tissue Collection and Histologic Analyses
Mice were anesthetized and killed at the times required by the experimental design. The distal ilea (10 cm) were resected, opened, rinsed of debris, and oriented from distal to proximal over a glass slide using HistoGel (Richard-Allan Scientific, Kalamazoo, MI) to prevent recoiling of intestinal tissue. Tissues were fixed in 10% buffered formalin or Bouin's fixative, embedded in paraffin, cut into 3-to 5-m sections, and stained with H&E. Histologic assessment of ileal inflammation was performed by a single pathologist in a blinded fashion, using a standardized semi-quantitative scoring system, as described previously. 21 
Generation and Characterization of Rat Anti-CCR9 Monoclonal Antibody (9B-1)
A synthetic peptide comprising the 25 N-terminal amino acids (Met1-Phe25) of murine CCR9 was coupled to keyhole limpet hemocyanin using N-succinimidyl-4-(maleimidomethyl)-cyclohexanecarboxylate. Lewis rats were then immunized with the mCCR9-KLH conjugate, and hybridomas were generated using splenocytes and the mouse myeloma X63-AG8.653 cell line. Antibodies were screened for their ability to selectively bind to synthetic mCCR9 peptide and to L1.2-CCR9 cells, which overexpress CCR9 (kindly provided by Dr Michael J. Bevan, Seattle, WA). To determine whether monoclonal antibody (mAb) 9B-1 neutralizes mCCR9 function, 1 ϫ 10 6 Fluo3-AM-loaded L1.2-CCR9 cells or RBL-C5aR cells 22 were incubated with 25 g 9B-1 or an isotypic control mAb in 0.5 mL buffer and agonist-induced (50 nmol/L CCL25 or 20 nmol/L C5a, respectively) intracellular calcium mobilization was measured as described. 22, 23 
Immunohistochemistry
Terminal ilea and colon from SAMP1/YitFc mice were harvested, snap frozen, and sectioned (5 m) on a cryostat (Microm HM505N, Walldorf, Germany) and then incubated with goat polyclonal antibody against CCL25 (AF-481) or goat IgG in the presence or absence of recombinant mouse CCL25 (R&D Systems, Minneapolis, MN). Secondary staining was conducted with rabbit anti-goat horseradish peroxidase-labeled antibody (Vector Laboratories, Burlingame, CA). Normal rabbit serum was used to reduce nonspecific binding (Sigma Chemical Co, St Louis, MO).
Lymphocyte Isolation
Mesenteric lymph node (MLN) and spleens were aseptically removed at the time of necropsy. Single-cell suspensions were obtained by gently pressing the MLN or spleen against a 100-m cell strainer. Spleen red blood cells were lysed by 15-minute incubation in 1ϫ ammonium chloride lysing reagent (BD PharM Lyse; BD Biosciences/PharMingen, San Jose, CA).
Flow Cytometry
Cells from indicated compartments were incubated with phycoerythrin-conjugated rat anti-mouse CCR9 (clone 242503) (R&D Systems) including anti-CD4 (clone GK1.5), CD8a (clone 53-6.7), CD19 (clone 1D3) for gating of lymphocyte populations, anti-L-selectin (clone MEL-14), and anti-integrin ␤ 7 (clone M293; BD Biosciences/PharMingen). Cells were fixed with 2% paraformaldehyde, and 3-4 color analyses were performed using the FACS Calibur System (Becton-Dickinson Immunocytometry Systems, San Jose, CA). Further analyses were performed using FLOWJo software (Tree Star Inc, Ashland, OR).
Real-Time Reverse-Transcription Polymerase Chain Reaction
Total RNA was isolated from homogenized tissue or cell pellets using the RNeasy Mini Kit (Qiagen, Valencia, CA) and converted to complementary DNA with the GeneAmp RNA PCR Kit (Applied Biosystems, Foster City, CA), along with random hexamers (0.75 g of total RNA; final reaction volume, 20 L). The levels of complementary DNA were quantified by real-time reverse-transcription polymerase chain reaction using an iCycler detection system (Bio-Rad, Hercules, CA). Primers for CCL25 were designed with Beacon Designer software (Premier Biosoft International; Palo Alto, CA) as follows: CCL25 forward 5=-CGTGCTGTGAGATTC-TACTTCC-3=, reverse 5=-CTCCTCACGCTTGTACTGTTG-3=. For real-time polymerase chain reaction, 400 nmol/L of each primer and 5% of the volume of the first-strand complementary DNA synthesis were used in a total volume of 25 L that included iQ SYBR Green Supermix (Bio-Rad), according to the manufacturer's directions. Each amplification reaction was performed in triplicate. Thermocycling conditions for the targets were as follows: 95°C for 3 minutes (iTaq DNA polymerase activation) and 40 cycles of 95°C for 15 seconds, 60°C for 15 seconds, and 72°C for 15 seconds. The expression of 18S RNA was measured in each sample as an endogenous control. The ratio of messenger RNA expression was calculated for each group of mice by the ⌬⌬Ct method (user bulletin no. 2, Applied Biosystems).
CCL25 Protein Extraction and EnzymeLinked Immunosorbent Assay
Terminal ilea from SAMP/YitFc and AKR mice were collected, snap frozen in liquid nitrogen, and homogenized in T-PER Tissue Protein Extraction Buffer (Pierce Biotechnology, Inc, Rockford, IL) supplemented with a protease inhibitor cocktail (Complete Roche Diagnostics, Penzberg, Germany) to prevent degradation of proteins during and after homogenization. Homogenates were centrifuged at 12,000 rpm, supernatants were collected, and total protein content was assayed using the Quick Start Bradford kit (Bio-Rad). Tissue homogenates were examined for CCL25 protein levels by a 3-step sandwich enzyme-linked immunosorbent assay as per the manufacturer's instructions (R&D Systems).
T-cell Culture and Cytokine Assay
Lymphocytes were cultured in 96-well round-bottom plates at 10 6 cells/mL in complete medium (RPMI 1640 with 10% fetal bovine serum, 2 mmol/L L-glutamine, and 1% penicillin/streptomycin) with or without anti-CD3 stimulation (clone 145-2C11, 5 g/mL; PharMingen, San Diego, CA). Supernatants were collected after 48 hours and stored at Ϫ70°C. A bead-based multiplex immunoassay (Upstate, Charlottesville, VA) was used to determine cytokine concentrations from cell culture supernatants. Bound cytokines were detected using a Luminex 100 array reader (Bio-Rad), and results were analyzed using the BioPlex Manager bead array software (Bio-Rad).
Therapeutic Interventions
SAMP1/YitFc mice at 7 and 39 weeks of age were injected intraperitoneally every other day for 3 days with mAbs (200 g each) against CCR9 (clone 9B-1, rat IgG1) and CCL25 (clone 89818, rat IgG2b; R&D Systems) or with irrelevant corresponding isotype control mAb. Mice were killed 1 week later, 16 -18 hours after the last injection.
Statistics
Statistical analyses were performed using the 2-tailed Student t test or 2-way analysis of variance. Data are expressed as mean and SEM. Statistical significance was set at P Ͻ .05.
Results

CCR9 Expression Is Increased in SAMP1/ YitFc Mice During Disease Induction
We examined the surface expression of CCR9 on CD4 ϩ and CD8 ϩ cells isolated from the spleen and MLN of SAMP1/YitFc mice and compared it with that of noninflamed AKR control mice at 4 -6 weeks of age. Phycoerythrinlabeled isotype antibody (mean fluorescence index [MFI] Ͻ 10 1 , not shown) and lymphocytes isolated from the respective organs of CCR9-deficient mice were used as controls ( Figure 1, dashed lines) . CCR9 ϩ T cells were identified in MLN and spleen of both control AKR and SAMP1YitFc mice ( Figure 1 ). An increase in the percentage of CCR9 ϩ lymphocytes was observed in SAMP1/YitFc lymphocyte subsets (70% and 68% increase within the CD8 ϩ population for MLN and spleen, respectively) compared with age-matched AKR mice ( Figure 1A and B) . The percentage of CCR9-expressing cells within the CD4 ϩ population increased only within the MLN compartment, whereas within the spleen the differences were not significant. The predominant CCR9-expressing population was identified within CD8 ϩ T cells of the MLN, as shown in Figure 1A . Furthermore, a CCR9 high subpopulation (MFI Ͼ 10 2 ) was present in both CD4 ϩ and CD8 ϩ T cells isolated from the MLN of SAMP1/YitFc mice, but not in similarly gated cells from control AKR mice without inflammation ( Figure 1A ).
CCL25 Levels Are Increased Within the Terminal Ileum of SAMP1/YitFc Mice Compared With Age-Matched Noninflamed AKR Mice
To determine whether the presence of inflammation influenced the expression of CCL25 within the terminal ileum, we assayed the tissue protein concentration of CCL25 using an enzyme-linked immunosorbent assay as described in Materials and Methods. CCL25 levels significantly increased in the inflamed ilea of SAMP1/YitFc mice compared with those of noninflamed AKR mice at 4 and 20 weeks of age ( Figure 1C ). We then compared the fluorescence intensity for CCR9 within the CD8 ϩ subpopulations of cells isolated from the MLN and spleen with that of thymocytes (MFI Ͼ10 2 ) and that of similarly gated CCR9-deficient cells (Figure 2A) . A subpopulation of cells with an MFI similar to that of thymocytes (CCR9 high ) was identified only within the MLN of SAMP1/YitFc mice ( Figure 2A , SAMP MLN) but not in MLN cells from AKR mice ( Figure 1A ). Further analyses showed that these CCR9 high cells expressed low levels of L-selectin ( Figure 2A ) and integrin ␤ 7 and ␣ E ( Figure 2B ). Because ␤ 7 integrin pairs only with ␣ E or ␣ 4 integrins, we may conclude that most CD8/CCR9 ϩ T cells coexpress the ␣ E ␤ 7 integrin heterodimer.
An
To begin to understand the role of the CD8 ϩ T-cell subpopulation in the disease process, we magnetically enriched for this population (96% purity) and determined their contribution to the overall cytokine profile after anti-CD3 stimulation compared with that of unfractionated lymphocytes. CD8 ϩ T cells produced comparable levels of interferon gamma and significantly higher levels of tumor necrosis factor ␣ (Figure 2C ), in support of their important role in the pathogenesis of ileitis.
Restricted Expression of CCL25 to the Small Intestine Is Preserved in Early and Late Chronic Murine Ileitis
It was previously believed that CCL25 expression was restricted to the small intestine and thymus 3, 6, 8, 13, 24, 25 ; however, a recent report has confirmed that in the setting of chronic inflammation, CCL25 may be aberrantly induced within the hepatic microvasculature of patients with primary sclerosing cholangitis. 14 These data suggest that specific inflammatory mediators may induce aberrant CCL25 expression at sites where it is not physiologically expressed. SAMP1/YitFc mice develop inflammatory infiltrates within their intrahepatic and extrahepatic biliary tree ( Figure 3A and B), sharing some features with human primary sclerosing cholangitis (unpublished results). Late in the course of the disease, mice also develop colonic infiltrates (caecitis, 15 not depicted) as well as hypertrophy of the MLN, 26 where most of the CCR9 ϩ T cells are found. We thus inquired whether CCL25 might be aberrantly expressed at these sites, enabling recruitment of CCR9-expressing lymphocytes. Tissues from SAMP1/YitFc mice with established ileitis (20 weeks of age) and from age-matched AKR mice were assayed for CCL25 messenger RNA using real-time reverse-transcription polymerase chain reaction. CCL25 expression was detected in the duodenum and ileum but not in the MLN, liver, or colon in mice with or without inflammation ( Figure 3C and D) .
The anti-CCR9 mAb 9B1 inhibited CCL25-induced calcium mobilization in L1.2-CCR9 cells. To determine whether 
AKR). (A and B)
Lymphocytes isolated from the indicated lymphoid compartments were incubated with CD4, CD8, and phycoerythrin-labeled anti-CCR9 mAb and analyzed by flow cytometry using CCR9-deficient lymphocytes (dashed line) from the respective organs and isotype antibody (MFI Ͻ 10 1 , not shown) as controls. Cells were gated on forward scatter (FSC), side scatter (SSC), and indicated populations. Representative data obtained from 3-4 mice at 4 -6 weeks of age from each mouse strain run in duplicate. (C) CCL25 protein concentration within the terminal ilea was determined by enzyme-linked immunosorbent assay as per methods (n ϭ 6 per strain and time point, *P Ͻ .05). mAb 9B-1 specifically neutralized CCR9 function, L1.2-CCR9 cells, which overexpress CCR9, were incubated with 25 g 9B-1 or an isotypic control mAb (rat IgG2a/) and agonist (50 nmol/L CCL25) and the CCL25-induced intracellular calcium mobilization was determined by spectrofluorometry as described. 22, 23 RBL-C5aR cells 22 similarly stimulated with 20 nmol/L C5a served as controls ( Figure 4A and B) . Only the anti-mCCR9 mAb 9B-1 inhibited CCL25-induced calcium mobilization in L1.2-CCR9 cells but failed to inhibit C5a-induced (20 nmol/L) calcium mobilization in RBL-C5aR cells ( Figure 4A and B) .
Immunoblockade of CCL25 and CCR9 Attenuated Induction but Not Maintenance of Chronic Murine Ileitis in SAMP1/YitFc Mice
To evaluate whether CCL25/CCR9 played a role in lymphocyte recruitment during the early or late stages of chronic murine ileitis, we administered 3 doses of functionblocking antibodies against CCR9, CCL25, or their respective isotype control mAbs to 7-week-old and 39-week-old SAMP1/YitFc mice. This treatment regimen effectively attenuated ileitis during prior studies, when the adhesion molecules PSGL-1 (mAb 4RA10) or the ␣ 4 integrins (mAb PS-2) were targeted. 27, 28 Terminal ilea were harvested 1 week later, 16 hours after the final injection. The severity of ileitis was determined by a pathologist in a blinded fashion, as previously described. 21 Compared with the isotype-treated controls, 8-week-old SAMP1/YitFc mice treated with anti-CCR9 showed significantly attenuated villous distortion (4.2 Ϯ 0.6 vs 6) and active (4.8 Ϯ 0.5 vs 6), chronic (2.6 Ϯ 0.8 vs 5.1 Ϯ 0.9), and total (11.6 Ϯ 1.5 vs 17 Ϯ 0.9) inflammatory indices ( Figure 5A ). Likewise, anti-CCL25 mAb attenuated villous distortion (2.8 Ϯ 0.4 vs 4.8 Ϯ 0.6) and active (2.8 Ϯ 0.4 vs 4.9 Ϯ 0.6), chronic (2.8 Ϯ 0.5 vs 4.9 Ϯ 0.6), and total (8.4 Ϯ 1.3 vs 13.5 Ϯ 1.8) inflammatory indices compared with control mice that were administered isotype antibodies ( Figure 5B ). Both treatments partially restored intestinal architecture ( Figure 5C ). By contrast, inflammation was unaffected by the anti-CCR9 or anti-CCL25 mAb during late chronic murine ileitis (40-week-old mice; Figure 5D ), suggesting that the disease becomes less dependent on this chemokine axis during its maintenance stages.
Expression of CCL25 Increased With Progression of Ileitis
The overall cytokine milieu in SAMP1/Yit mice is different during the early and late stages of the disease. Th1 polarization predominates early, followed by combined Th1/ Th2 responses subsequently. 29 We therefore compared the expression of CCL25 in 4-week-old mice with that of 40-week-old mice, using immunohistochemistry and enzyme-linked immunosorbent assay, to determine whether differences in overall cytokine expression may alter the expression of CCL25 and result in the decreased therapeutic efficacy observed during late disease ( Figure 6A-E) . However, this was not the case, and even a further increase in CCL25 protein levels was observed in the ileum but not in the colon during late disease.
Decreased Levels of Lymphocytes Expressing CCR9 in SAMP1/YitFc Mice During Late Disease
We then compared the expression of CCR9 in lymphocytes isolated from the MLN and spleen during early disease (when immunoblockade was efficacious) with that seen in lymphocytes during late disease, when no therapeutic benefit was appreciated ( Figure 5 ). CCR9 expression, which was increased in SAMP1/YitFc CD4 ϩ and CD8 ϩ populations during early disease compared with control mice ( Figure 1A and B) , decreased by 40 weeks of age ( Figure 7A and B) . In addition, the CD4 ϩ and CD8 ϩ CCR9 high subpopulations, present at the peak of the disease, were virtually absent ( Figure 7A ). 
Decreased CCR9 Expression Occurs Despite Increased Production of Endogenous Interleukin-4 During Late Ileitis
The specific signals that trigger the expression of CCR9 and CCL25 above physiologic levels are not known. Interleukin (IL)-4 has been shown to increase the total percentage of cells expressing CCR9 and the surface density of receptor expression when added to cells in vitro. 30 To determine whether CCR9 expression may be regulated by autocrine mechanisms, we harvested lymphocytes from 8-and 40-week-old SAMP1/YitFc mice, cultured them under anti-CD3 stimulation for 48 hours, and assayed their IL-4 production from the culture supernatants. IL-4 production by cells isolated from mice during late disease was significantly higher compared with that of cells isolated from mice during early disease ( Figure 7C ). This pattern is different from that of CCR9 expression, which was higher during early disease. These data suggest that the regulation of CCR9 expression in vivo is more complex than that previously observed in vitro.
Discussion
We investigated whether CCL25/CCR9 play a role in chronic inflammatory trafficking to the small intestine using the SAMP1/YitFc model of chronic ileitis. 15, 26 This strain differs from other animal models of inflammatory bowel disease, because the site of inflammation coincides with the restricted location of CCL25 expression. 31 We showed that the levels of CCL25 increased in inflamed small intestine compared with noninflamed mice and that further increases occur as the inflammation progresses. However, in this mouse model, different from prior reports in patients with primary sclerosing cholangitis, 14 we did not observe aberrant extraintestinal expression of CCL25. Lymphocytes expressing the receptor CCR9 underwent early inflammation-driven expansion, predominantly of the CD8 ϩ population, and a population of lymphocytes with an MFI for CCR9 similar to that of thymocytes was detected only in inflamed mice. Conversely, during late disease, the percentage of CCR9 ϩ cells decreased and the CCR9 high subpopulation was absent, supporting potential extinction of pathway use.
We showed that the CCR9/CCL25 receptor/ligand pair predominantly plays its role during induction of spontaneous chronic murine ileitis, because neutralizing antibodies attenuate early disease when receptor expression is at its maximum. By contrast, blockade of CCR9 or CCL25 was not sufficient to attenuate inflammation during the late stages of the disease. At this stage, CCR9 is down-regulated and it is likely that other inflammatory/inducible chemokines and chemokine receptors offset the effect of CCL25/CCR9 immunoblockade.
The expression of MAdCAM-1, which also plays a pivotal role in intestinal trafficking, is increased in the chronically inflamed small and large intestine. 32 It is also aberrantly expressed in the chronically inflamed pancreas and liver, where it recruits lymphocytes that express integrin ␣ 4 ␤ 7 to extraintestinal sites. 33, 34 Thus, chronic inflammatory signals increase the expression of adhesion molecules/chemokines at effector sites and trigger aberrant expression at sites where they are not physiologically expressed. 35 Although CCL25 has been considered a strictly homeostatic chemokine, 36,37 more recent data have led to the suggestion that its expression may be induced under the appropriate conditions. 14, 38 SAMP1/YitFc mice develop extraintestinal manifestations reminiscent of those seen in human inflammatory bowel disease (ie, pyoderma-like skin involvement, ocular lesions, joint inflammation, and intrahepatic and extrahepatic periportal infiltrates). We hypothesized that some of these extraintestinal manifestations could be mediated by recruitment of small intestinal-specific CCR9 ϩ T cells to these sites, where CCL25 may be aberrantly expressed. However, in this mouse model, CCL25 was not detected outside the small intestine, indicating that its restricted pattern of expression is conserved. Whether this is due to interspecies variation or whether sustained chronic inflammation is required for extraintestinal induction remains to be elucidated. The total percentage of CCR9 ϩ cells and the density of surface expression increased in ileitis, as shown by the presence of a CCR9 high subpopulation that was unique to inflamed mice. However, the specific signals that mediate the up-regulation of CCR9 have yet to be identified. Data derived from in vitro studies suggest that IL-4 may be an important factor. 30 Nonetheless, these studies did not predict the in vivo scenario, because CCR9 expression decreased during late disease despite increased local levels 29 and endogenous IL-4 production by the assayed cells.
Our data show that throughout early disease, this predominantly homeostatic chemokine axis (already operational in the ileum) continues to be used as an important recruitment pathway by pathogenic lymphocytes. However, as the disease progresses, CCL25/CCR9 appear to be insufficient to sustain the demand for proinflammatory cells to the effector site, resulting in up-regulation of inducible molecules that respond to inflammatory signals (eg, MAdCAM-1, ICAM-1, and inflammatory chemokines). 39, 40 Yet, there does not appear to be a switch from constitutive to inflammatory pathways but rather continuous overlap, without clear demarcation of the replacement of one axis by another. During the later phase, redundant inflammatory pathways are acquired that sustain continuous dysregulated recruitment to the effector site. 27 The recruitment process then becomes autonomous and refractory to regulation, resulting in chronic inflammation, tissue destruction, and loss of function.
A significant number of patients with CD become refractory to standard therapies, and even the most widely used biologic therapeutic agent (ie, infliximab, an antibody against tumor necrosis factor ␣) is effective in only 70% of patients. 41 Patients with refractory CD often require repeated use of corticosteroids, with potentially devastating side effects, or undergo palliative surgeries to remove strictures, treat abscesses, or correct fistulas. Unfortunately, other cytokine-based therapies, such as the anti-inflammatory cytokine IL-10 and recombinant IL-11, have had limited success. 42, 43 Therefore, alternative therapeutic modalities that target other pathways of chronic intestinal inflammation (eg, trafficking) must be evaluated in CD. 44 To that effect, clinical trials to test the safety and efficacy of the small molecule antagonist Traficet EN, CCX282, which targets the CCL25/CCR9 axis, have been completed (http://www.clinicaltrial.gov/ct/show/NCT00102921) in patients with CD. Yet, to our knowledge, little preclinical information to describe the efficacy of this therapeutic strategy has been made available and none has been published. It is worth noting that, because the chemokine is not known to be expressed in normal or inflamed colon, any data generated from colitic models may be of limited interest; yet models that develop inflammation in the small intestine may provide valuable information. Although caution is needed when extrapolating conclusions drawn from animal models, our data suggest that inclusion of patients with small intestinal CD and with increased circulating CCR9-expressing cells (as previously shown by Papadakis et al 45 ) may enhance the response rate of subsequent clinical studies that target this chemokine/receptor axis. 
